A real change is on the horizon. In October 2021, Facebook announced that it would rebrand itself as ‘Meta’, and this generated high levels of public interest in the metaverse for the first time. Definitions for the metaverse vary and there is still much uncertainty in its eventual future manifestation. It is perhaps best defined as a fully immersive parallel digital reality where users will be able to interact at a scale previously unimagined.1 The advent of the metaverse could have transformational impact on every aspect of human life, from our social interactions to what we ascribe real value to. Just as the Internet has completely transformed health, the metaverse will redefine virtual and physical possibilities in health.2 This will have major implications for our health and for healthcare delivery. The coming of age of the metaverse is in due largely to the maturation of technological advances in artificial intelligence and devices that enable the delivery of mixed, augmented and virtual reality, along with cryptography, the catalyst behind web3, and increased computing power.
There has been an increase Group A Streptococcal (GAS) infections in recent months, which has led to at least 8 deaths in children. Although GAS rates are higher than expected for this time of year, they have been higher at periods over the last decade. GAS causes a range of infections including Scarlet Fever and also more severe invasive disease.
For more information on management, see: Scarlet fever: a guide for general practitioners. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649319/
The Centor score can be used to assess the probability of an illness being GAS pharyngitis: Tonsillar exudates, tender anterior cervical adenopathy, absence of cough, history of fever (>38 °C). Penicillin V (or Amoxicillin) is the preferred treatment unless contra-indicated in which case an alternative such as a cephalosporin or clarithromycin can be given.
Scarlet Fever and invasive GAS disease are notifiable and should be reported to the local health protection unit. Contacts (although at higher risk of GAS infection) do not generally need antibiotics unless symptomatic. See contact tracing flowchart for details. Health protection teams are responsible for contact tracing.
Antibiotics should only be administered:
1. To mother and baby if either develops invasive group A streptococcal disease in the neonatal period (first 28 days of life);
2. To close contacts if they have symptoms suggestive of localised Group A streptococcal infection, i.e. sore throat, fever, skin infection;
3. To the entire household if there are two or more cases of invasive group A streptococcal disease within a 30 day time period.
Oral Penicillin V is the drug of first choice where chemoprophylaxis is indicated. Azithromycin is a suitable alternative for those allergic to penicillin. Some areas of England are now reporting shortages of liquid antibiotics.
There is currently considerable media coverage and some public anxiety in the UK about Group A streptococcal (GAS) infections. Journalists who write about cases of infectious diseases need to understand the principles of the Poisson distribution. Events such as infections can sometimes cluster in time or space due to chance, and not because there is an underlying cause behind the cluster of cases.
Some journalists and doctors are stating that the cases of Group A streptococcal infections we are currently seeing in the UK are from lower levels of immunity because of Covid-19 control measures over the last 2.5 years. This is not necessarily the case and needs further investigation. The UK has experienced large outbreaks of Group A streptococcal infections in the past. For example, the UK had a large outbreak of Group A streptococcal infections between September 2015 and April 2016 (the largest since 1969), resulting in PHE issuing an alert.
The current cluster of Group A streptococcal infections won’t be the last we will see in the UK. Outbreaks of this and other infections will continue to occur. What is important is that our public health agencies and the NHS have the capacity to investigate and manage any outbreaks.
Witing in the Journal of the Royal Society of Medicine, myself, Austen El-Osta and Chris Rowe set out a vision for building sustainable, self-driven healthcare spanning primary care, secondary care and the wider health and social care system has been set out by medical innovators. Self-driven healthcare (SDH) is an umbrella term introduced by Innovate UK, the UK’s national innovation agency, to conceptualise aspects of healthcare delivery that can support people in becoming more engaged in managing their own health and wellbeing, rather than being passive receivers of healthcare.
In our paper, we describe an SDH ecosystem that supports individuals to take more ownership of their health and wellbeing and in recording their own data (e.g. weight, blood pressure) using a phone app, tablet, computer or Bluetooth device. This self-generated data would then be uploaded onto a secure online SDH portal which holds all their health records, including those generated in the wider healthcare system.
Individuals would also enter other data such as what medication they had taken that day, the food they had eaten or the exercise they had done. They may even have a range of other devices that automatically record and upload useful information, such as environmental data about local air quality that day. A personalised dashboard would automatically present the user with their ‘digital twin’ and the portal may also be enabled to routinely offered insights and actionable advice, including microlearning and behaviour change interventions and a holistic picture of the person’s overall health and wellbeing status.
The SDH approach must create better access to all sections of the community rather than just wealthier and more technically literate individuals. It is also crucial that the SDH movement does not exacerbate inequalities due to the digital divide. How SDH is adopted in the future is very important, especially when it is applied to help enhance the consumer health system by trying to link it effectively with state-funded NHS health and social care systems. It will be important to determine if these online environments will be provided by expanding the NHS App, for example, or by commercial companies.
A recent article in the British Medical Journal discusses work-related stress and burnout in healthcare workers. These are important problems in the NHS workforce in the UK a well as amongst healthcare workers in other countries. Addressing the underlying cause, which may relate to factors such as workplace demand, relationships, and support is necessary for sustained recovery and full engagement with work.
Healthcare workers may experience guilt or shame due to stigma, preventing them from seeking help if they experience work related mental illness. Time off work and workplace changes to control the triggers may be necessary to allow recovery and sustainable return to work.
Healthcare workers experiencing work related stress can seek support from colleagues, their own GP, occupational health, and specialised services for healthcare workers such as local mental health and wellbeing hubs and NHS Practitioner Health.
Our recent article in the Journal of the Royal Society of Medicine discuses the diagnosis and management of Monkeypox in UK primary care settings but is also relevant to primary care clinicians working in other countries outside West and Central Africa that have seen Monkeypox cases in 2022.
Since its discovery in 1958 in monkeys, the Monkeypox virus has been rarely found outside west and central Africa until the current global outbreak. The first human case of the virus was in an infant from the Democratic Republic of Congo (DRC) in 1970; the infection has since spread to other regions, primarily in Africa. The first case of the current outbreak was confirmed on 6 May 2022, in the UK and was linked to travel to Nigeria. Two subsequent UK cases were detected a week later; however, neither affected individuals reported contact with the primary case in the UK nor travel to Africa.
On 23 July 2022, the World Health Organization (WHO) declared the current Monkeypox outbreak a public health emergency of international concern, as the number of cases increased rapidly around the world. As of 9 September 2022, 57,016 cases have been confirmed in 96 non-endemic regions, with the UK having one of the highest number of cases worldwide (3484 cases).
As we understand more about the current outbreak, particularly the community transmission of the virus, primary care clinicians may be the first point of healthcare access. Therefore, awareness of the signs and symptoms of the disease and current management strategies is crucial to providing optimal care and advice to patients.
Much of the discussion about vaccination in the UK is on Covid-19 and flu vaccines or vaccines for children. But there are also other important vaccines for adults – such as for shingles – where there is scope to increase uptake and improve health outcomes for older people and the immunocompromised.
Shingles is caused by the reactivation of latent varicella zoster virus (VZV); sometimes decades after the primary chickenpox infection. For some people – particularly the elderly and the immunocompromised – shingles can be a very unpleasant illness with significant complications.
In the UK, two vaccines are licensed for shingles:
– Zostavax which contains live, attenuated virus and which is given as a single dose.
– Shingrix which is a recombinant vaccine and which his given in two doses.
The main target group for shingles vaccination in the UK is people aged 70-79 years. Most people in this group will receive the Zostavax vaccine. People in this age group who are immunocompromised should receive the Shingrix vaccine. The rationale for vaccinating the elderly is because complication rates are much higher in this group. For example, hospital admission rates for shingles (zoster) are around 20 times higher in people aged 75 and over than those aged 15-59.
When people turn 70, they should receive an invitation for shingles vaccination from their GP. If they didn’t take up the offer of a vaccination at that time, they can still get a shingles vaccination until they are 79. Once they turn 80, you will no longer be eligible for shingles vaccination. Shingles is a disease that has many complications in the elderly. It can result in considerable pain and discomfort and reduce your mobility. In more severe cases, it may require hospital treatment as an outpatient or inpatient. Vaccination reduces these risks substantially.
Our new paper in the International Journal of Integrated Care reviews the role of multidisciplinary team (MDT) meetings in the management of multimorbidity in primary care. MDTs bring together professionals to work together to improve health outcomes for patients. MDT meetings are often recommended as a critical aspect of integrated care in guidance and opinion pieces, but it is not clear how and to what extent their use improves outcomes for patients with multimorbidity. Our review aimed to fill this knowledge gap.
We found limited evidence that supports the implementation of MDT meetings in primary care settings for individuals with multimorbidity. There were also substantial problems with the methodological rigour of previous studies on MDT meetings in primary care. Although MDT meeting are a key strategy for delivering comprehensive integrated care, there is a lack of evidence concerning the efficacy of MDT meetings in primary care. The complexity of interventions meant that causality cannot be attributed to the MDT meeting alone.
There is an urgent need generate more evidence about MDT meetings in primary care. Future research should focus on a broader set of participant characteristics, contextual adaptation, and innovation. Decision makers and clinicians should also take advantage of the recent technological progress in healthcare.
With England’s NHS under immense pressure even before the full onset of winter, here are 20 tips on how you can make the most of the NHS, use health services more appropriately, and obtain the care you and your family need to protect your health and wellbeing.
1. Attend for appointments for medication reviews and for the management of long-term conditions when invited.
2. Take-up the offer of Covid-19 and flu vaccinations if you are eligible. Make sure you are up to date with any other vaccinations you are eligible for. Attend for health screening appointments when invited.
3. Use the NHS app to book appointments, view your GP medical record and order repeat prescriptions.
4. Be aware of the range of options for NHS care – including opticians, pharmacists, self-referral services (e.g. podiatry, IAPT, smoking cessation), and NHS 111.
5. Use the NHS electronic prescription service so that your prescription is sent directly to a pharmacy.
6. For queries about hospital care, contact the hospital PALS team rather than your GP.
7. Apply for online access to your hospital records if this is available.
10. Don’t Smoke.
11. Exercise regularly including outdoors so that you get some sunlight exposure. This will also help with seasonal affective disorder (SAD).
12. Eat 5 portions of fruit & vegetables every day and eat plenty of high-fibre foods.
14. Limit your sugar & salt intake.
15. Limit your alcohol intake to a safe level.
16. Take time to improve your mental health; including by meeting regularly with friends and family.
17. Check your own blood pressure.
18. Take your medication as prescribed.
19. Get a good night’s sleep.
20. Listen to experts on health issues and not random people on social media.
Our new study in JRSM Open led by Dr Raj Chandok and Dr Poonam Madar examines factors influencing Covid-19 vaccine hesitancy among South Asians in London. Vaccines have a key role in suppressing serious illnesses, hospitalisations and deaths from Covid-19. London has amongst the lowest Covid-19 vaccination rates in the UK and it’s important to understand the factors behind this so we can work better with local communities to address this key public health challenge. This includes looking at factors such as confidence in Covid-19 vaccines, complacency about the severity of illness arising from Covid-19, communication about vaccines in both the mainstream media and social media, and the context in which people live and work.